Related amyloid burden and cortical atrophy in individuals with subtle cognitive decline
Abstract
Subtle cognitive decline represents a stage of cognitive deterioration in which pathological biomarkers may be present, including early cortical atrophy and amyloid deposition. Using individual items from the Montreal Cognitive Assessment and k‐modes cluster analysis, we previously identified three clusters of individuals without overt cognitive impairment: (1) High Performing (no deficits in performance), (2) Memory Deficits (lower memory performance), and (3) Compound Deficits (lower memory and executive function performance). In this study, we sought to understand the relationships found in our clusters between cortical atrophy on MR and amyloid burden on PET.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 23, 2022
- Source ID
- 10.1111/jon.13055
Entities
People
- Athene Lee
- Indra Neil Sarkar
- Jessica Alber
- Leslie Ann D Brick
- Louisa Thompson
- Shanti Mechery
- Tess E K Cersonsky
Organizations
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Brown University
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Lundbeck Foundation
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Science Foundation
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Rhode Island